The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Suzanne LentzschThe Multiple Myeloma Hub were pleased to speak to Suzanne Lentzsch, Columbia University, New York, US, about the treatment of AL amyloidosis in 2019. She highlights the importance of correct diagnosis and recommends its confirmation by mass spectrometry. Although CyBorD remains the standard of care, the addition of daratumumab might enhance the response. She states that allo-HSCT is still a popular choice especially in patients with early-stage disease and gives an overview of the clinical developments in the treatment of relapsed multiple myeloma, such as promising results from venetoclax studies.
How should we treat AL amyloidosis in 2019?